SCHEMBL12905282

SCHEMBL12905282

CN1CCc2cccc(Cl)c2N1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.54
ADRA2A P08913 2/20 0.53
ADRA2B P18089 2/20 0.53
ADRA2C P18825 2/20 0.53
CYP2D6 P10635 1/20 0.53
ADRA1D P25100 1/20 0.53
ADRA1A P35348 1/20 0.53
ADRA1B P35368 1/20 0.53
NPSR1 Q6W5P4 1/20 0.51
DRD2 P14416 3/20 0.43
DRD3 P35462 3/20 0.43
HTR2C P28335 3/20 0.39
HTR2B P41595 2/20 0.39
MAOA P21397 2/20 0.38
MAOB P27338 2/20 0.38
DRD1 P21728 2/20 0.38
DRD5 P21918 2/20 0.38
DRD4 P21917 1/20 0.38
HTR2A P28223 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2625796 0.81 NOTUM (0.57) NOTUMADRA2AADRA2BADRA2CCYP2D6
SCHEMBL12905288 0.79 MAOA (0.39) NOTUMADRA2AADRA2BADRA2CCYP2D6
SCHEMBL12905298 0.79 ALOX12 (0.47) NOTUMADRA2AADRA2BADRA2CCYP2D6
SCHEMBL12905291 0.78 MAOA (0.38) NOTUMADRA2AADRA2BADRA2CCYP2D6
SCHEMBL12905306 0.75 DRD3 (0.50) DRD2DRD3HTR2CHTR2BDRD1
SCHEMBL2625802 0.74 NOTUM (0.50) NOTUMADRA2AADRA2BADRA2CCYP2D6
SCHEMBL12905310 0.74 AADAT (0.38) NOTUMADRA2AADRA2BADRA2CCYP2D6
SCHEMBL22193281 0.73 NOTUM (0.53) NOTUMADRA2AADRA2BADRA2CCYP2D6
SCHEMBL8979357 0.73 NOTUM (0.53) NOTUMADRA2AADRA2BADRA2CCYP2D6
SCHEMBL18329551 0.73 NOTUM (0.53) NOTUMADRA2AADRA2BADRA2CCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110003820-A1 PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE MERZ PHARMA GMBH & CO. KGAA (DE) 2011-01-06 US disclosed
US-20110003820-A1 PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE MERZ PHARMA GMBH & CO. KGAA (DE) 2011-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003820-A1 PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE GRM5, GRIK5, GRK5 NOTUM 2035/4885ADRA2A 1536/4885ADRA2B 1489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.